Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Andrée Boucher; Shereen Ezzat; Sebastien Hotte; Irina Rachinsky; Murali Rajaraman; Dean Ruether; Sam M. Wiseman; James Brierley; Cheryl Ho; Monika Krzyzanowska; Nathan Lamond; Marie Hélène Massicotte; Shereen Joseph; Kassey Herscovitch; Lindsey Sikora; Eric Winquist

doi:10.1016/j.oraloncology.2021.105477

Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Andrée Boucher, Shereen Ezzat, Sebastien Hotte, Irina Rachinsky, Murali Rajaraman, Dean Ruether, Sam M. Wiseman, James Brierley, Cheryl Ho, Monika Krzyzanowska, Nathan Lamond, Marie Hélène Massicotte, Shereen Joseph, Kassey Herscovitch, Lindsey Sikora, Eric Winquist

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.

Original language	English
Article number	105477
Journal	Oral Oncology
Volume	121
DOIs	https://doi.org/10.1016/j.oraloncology.2021.105477
State	Published - 1 Oct 2021
Externally published	Yes

Keywords

Differentiated thyroid cancer
Head and Neck Neoplasms
Iodine Radioisotopes
Lenvatinib
Protein Kinase Inhibitors
Radioactive iodine
Refractory
Resistant
Sorafenib
Thyroid Neoplasms

ASJC Scopus subject areas

Oral Surgery
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2021.105477

Cite this

Boucher, A., Ezzat, S., Hotte, S., Rachinsky, I., Rajaraman, M., Ruether, D., Wiseman, S. M., Brierley, J., Ho, C., Krzyzanowska, M., Lamond, N., Massicotte, M. H., Joseph, S., Herscovitch, K., Sikora, L., & Winquist, E. (2021). Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer. Oral Oncology, 121, Article 105477. https://doi.org/10.1016/j.oraloncology.2021.105477

@article{6c70a5dde85044b5bb1da76c1c158013,

title = "Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer",

abstract = "Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.",

keywords = "Differentiated thyroid cancer, Head and Neck Neoplasms, Iodine Radioisotopes, Lenvatinib, Protein Kinase Inhibitors, Radioactive iodine, Refractory, Resistant, Sorafenib, Thyroid Neoplasms",

author = "Andr{\'e}e Boucher and Shereen Ezzat and Sebastien Hotte and Irina Rachinsky and Murali Rajaraman and Dean Ruether and Wiseman, {Sam M.} and James Brierley and Cheryl Ho and Monika Krzyzanowska and Nathan Lamond and Massicotte, {Marie H{\'e}l{\`e}ne} and Shereen Joseph and Kassey Herscovitch and Lindsey Sikora and Eric Winquist",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.oraloncology.2021.105477",

language = "English",

volume = "121",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Ltd.",

}

Boucher, A, Ezzat, S, Hotte, S, Rachinsky, I, Rajaraman, M, Ruether, D, Wiseman, SM, Brierley, J, Ho, C, Krzyzanowska, M, Lamond, N, Massicotte, MH, Joseph, S, Herscovitch, K, Sikora, L & Winquist, E 2021, 'Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer', Oral Oncology, vol. 121, 105477. https://doi.org/10.1016/j.oraloncology.2021.105477

TY - JOUR

T1 - Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

AU - Boucher, Andrée

AU - Ezzat, Shereen

AU - Hotte, Sebastien

AU - Rachinsky, Irina

AU - Rajaraman, Murali

AU - Ruether, Dean

AU - Wiseman, Sam M.

AU - Brierley, James

AU - Ho, Cheryl

AU - Krzyzanowska, Monika

AU - Lamond, Nathan

AU - Massicotte, Marie Hélène

AU - Joseph, Shereen

AU - Herscovitch, Kassey

AU - Sikora, Lindsey

AU - Winquist, Eric

PY - 2021/10/1

Y1 - 2021/10/1

N2 - Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.

AB - Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.

KW - Differentiated thyroid cancer

KW - Head and Neck Neoplasms

KW - Iodine Radioisotopes

KW - Lenvatinib

KW - Protein Kinase Inhibitors

KW - Radioactive iodine

KW - Refractory

KW - Resistant

KW - Sorafenib

KW - Thyroid Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85112269140&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2021.105477

DO - 10.1016/j.oraloncology.2021.105477

M3 - Review article

C2 - 34388408

AN - SCOPUS:85112269140

SN - 1368-8375

VL - 121

JO - Oral Oncology

JF - Oral Oncology

M1 - 105477

ER -

Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this